The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

The "takings clause" in the Fifth Amendment to the U.S. Constitution might keep the federal government from creating ...

Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23. The ...

The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...

In the middle is the FDA trying to referee the high-stakes and increasingly ... copycat versions of its juggernaut diabetes ...